



Together with metallurgical processes, microbiology is the
technological and scientific field that has been used from
ancient times both to improve living conditions and to in-
crease survival opportunities by transforming risks into chal-
lenges. After humans became sedentary, and agriculture be-
gan to transform food availability, acquiring new materials
that either never existed before (metallurgy) or existed at
very low levels (microbiology) became the impetus for a new
human activity: industry. Industry has been usually defined
as the art and ability to transform raw materials into new and
useful products. Food was most likely one of the first prod-
ucts that humans tried to ensure. While agriculture gave
humans the possibility of having enough food, weather and
climatic conditions limited its year-round availability. Thus,
the challenge was being able to maintain sufficient food
stocks in good condition throughout the year, until the next
harvest. Microbiology was involved in this process by
chance and, as a result (probably after hundreds of failed
attempts), bread, cheese, wine and beer have been consumed
for thousands of years. In fact, yeast was used to produce
beer in Sumeria before 7000 BC, and Assyrians already pro-
duced wine in 3500 BC. These beverages are obtained through
the action of microorganisms, and the final products can be
stored for longer periods than the original raw materials. Two
main characteristics defined early industrial processes: (i)
They appeared after a coincidental observation (i.e. the fer-
mentation of sugar present in fruits or grains to yield alco-
hol), which human societies then gradually learnt to control
and to make more profitable. (ii) Although processes derived
from these observations were optimized and became increas-
ingly profitable, knowledge of them was a result of experi-
ence, and the reasons why, e.g., fruit must turned into wine or
milk turned into cheese, were not known.
Such was the state-of-the-art until the second half of the
nineteenth century, when two events marked the beginning of
industrial microbiology: (i) The scientific phenomena res-
ponsible for early industrial processes started to be under-
stood and well known. Around 1860, Pasteur discovered the
major role of yeast in the food and beverage industries. As a
result, he has been considered the father of modern microbi-
ology. The idea that microorganisms were living material that
could be used as elementary chemical reactors became wide-
ly accepted. Thus, industrial microbiologists could address
the same concepts as engineering chemists (especially ener-
gy and mass balances). (ii) The capability to control and
make these processes much more profitable (including the
use of more efficient microbial species or strains) increased.
This capability derived from the recognition that the condi-
tions at which microbial “machines” give an optimal yield are
controlled, external ones (pH, temperature, pressure, feed
flow) that do not affect the machine itself: the microorgan-
isms used grow also naturally in the environment. Further-
more, all the processes focus on maintaining the status quo,
trying to avoid variations that might affect the yield. Even
today, some of the regulations for whisky and wine produc-
tion are related to the need to use endogamic yeast. There-
fore, mutation, degradation or contamination of the working
microbial species are risks to be avoided.
That had been the situation until a few decades ago, and
is the core of classic industrial microbiology [3]. Microbial
processes are involved in food, pharmaceutical, fine-chemi-
cal, cosmetic, energy and new-material industries. It has been
estimated that these processes move currently more than US$
70 billion worldwide [1]. The replacement of petroleum-based
fuels by yeast fermentation-obtained ethanol (bioethanol)
will mean a new revolution in the energy market and it will
fulfill environmental requirements. For several reasons,
microbiological processes with industrial applications are
usually much more advantageous than any other industrial
processes, accounting for the strong continued interest in this
field. First, the specific ability of a given microorganism to
produce a particular molecule can be exploited. This mole-
cule can be a secondary metabolite or, more directly, a by-
product of microbial metabolism. While chemical industrial
processes may yield the same product, the process is often
more complex, involving more pathway steps, and/or mixed
with some undesirable byproducts. Second, the molecules
obtained from microorganisms are synthesized under mild
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conditions, resulting in less energy and equipment costs com-
pared with chemical synthetic processes. Nevertheless,
industrial microbiology still has some limitations, due to the
need of having the working microorganism fully operative
and protected against mutation, other microbial contami-
nants, competitors, and environmental changes.
During the last few decades, molecular biology and sub-
sequently genetic engineering have contributed to a better
understanding of both the ultimate mechanisms involved in
industrial microbial processes and the main conditions influ-
encing them. For the first time, it has been possible to modi-
fy selectively and efficiently these microbiological machines;
their natural abilities have been improved or new ones
derived from other organisms (either microbes or even
plants) have been added to them. As a consequence, these liv-
ing machines have turned out to be more productive and
more resistant against changes, and can thus be used for other
new biochemical reactions.
Over the last 20 years, new or more efficient industrial
processes involving microorganisms have been launched,
yielding purer, less expensive products or substances not
available using classical chemical methods. In general, it is
now possible to: (i) convert secondary reactions into main
metabolic pathways; (ii) optimize productions and yields;
(iii) change the original metabolic pathways to allow the use
of less expensive raw materials, or to obtain previously
unknown molecules; and (iv) use the enantiomeric properties
of enzymes to obtain new chiral molecules. The long list of
products obtained by these methods increases every year, and
many industrial areas are involved. The products most com-
monly obtained in industrial microbiology include:
• Pharmaceutical proteins (human interferon, epidermal
growth factor and hemoglobin, antigens for hepatitis-B
virus, stabilizers for erythropoietin and human chorionic
gonadotropin) obtained from microorganisms such as
Saccharomyces cerevisiae, Pichia pastoris, Hansenula
polymorpha or Agrobacterium tumefaciens.
• Recombinant enzymes for industrial processes obtained
from microorganisms. The industrial enzyme market for
non-therapeutic uses, such as food, detergents, textiles,
leather, pulp and paper industry reached US $2 billion in
2000 [2]. Microbial lipases are of special interest because
of their stability in organic solvents and their lack of a
requirement for cofactors, their broad substrate specifici-
ty and their high enantioselectivity. Lipolase™ from
Novozyme, launched in 1994, is the first recombinant
lipase; it was obtained by cloning the Thermomyces
lanuginosus (formerly Humicula lanuginosa) lipase gene
into the Aspergillus orzyae genome [4].
• Antibiotics, including biosynthetic penicillin V and natu-
ral penicillin G. Of the 12,000 antibiotics known in 1995,
more than 20% can be produced by filamentous fungi.
Biosynthetic and semisynthetic penicillins and cefalospo-
rins have a market reaching US $15,4 billion. 
• Inmunosuppresive agents, including cyclosporin A, ob-
tained from Tolypocladium nivenum, or mycophenolate
mofetil, from several Penicillium species.
• Hypocholesterolemic agents including lovastatin, obtained
from Aspergillus terreus, and pravastatin, from Penicillium
citrium, which have a market of US $15 billion.
• Antitumoral agents such as taxol, first discovered in
plants but later transferred to and produced by Taxomyces
andreanae; in 2000 it comprised 10% of total sales for
Bristol Myers-Squibb, reaching US $1 billion [5].
• Mycotoxins including adrenalin inhibitors, estrogens and
anabolic agents for cattle and sheep, or gibberellins used
in brewing and malting industries.
• Pigments, including the carotenoid astaxanthin from
Phaffia rhodozyma, and β-carotenoid from Blakeslea
trispora, used in food and textile industries.
• Polyunsaturated fatty acids, including γ-linoleic acid
from Mucor circinelloides, and arachidonic acid from
Mortierella isabellina. 
This voyage is only at its beginnings, and many challenges
still face us. For example, the technology suitable to synthe-
size all these molecules in a less expensive, more efficient
way, using carbon dioxide as the carbon source, water as the
electron acceptor, and sunlight as the driving energy, is need-
ed. Many scientists have tried to solve this equation for years,
unaware that such a process namely, photosynthesis, already
exists and has been used by photosynthetic organisms (many
microorganisms and all plants) for millions of years. As a
final example, the previously mentioned switch from petrole-
um-based fuels to bioethanol will mean a new revolution in
the energy market, and will change significantly internation-
al commercial relationships. Nevertheless, this is only the
first step towards the final goal: the hydrogen-based battery.
Microbiology will no doubt take part in this task as well.
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